For research use only•All products are intended strictly for laboratory research purposes only• Not for human consumption•
Cart rewardsFREE Shipping on $150+·5% OFF Orders $250+·10% OFF + VIP Gift Orders $400+
PEPTIDESResearch Use Only
Research Blog
GH Secretagogues

CJC-1295, Ipamorelin and Tesamorelin: How GH Secretagogues Differ

Beligas Research Team·Oct 18, 2026· 7 min read

GHRH analogues and ghrelin-receptor agonists act through different receptors. Here is how each peptide is built, what published studies report, and why the two classes are studied together.

Growth-hormone secretagogues fall into two pharmacological classes. GHRH analogues act on the GHRH receptor of pituitary somatotrophs; ghrelin mimetics act on the growth-hormone secretagogue receptor (GHSR-1a). Understanding which class a peptide belongs to is the starting point for any experimental design.

CJC-1295: a stabilised GHRH analogue

CJC-1295 is a GHRH(1–29) analogue with four amino-acid substitutions that resist enzymatic degradation. The version with a Drug Affinity Complex (DAC) binds serum albumin covalently, extending its half-life to several days in a published study in healthy adults (Teichman et al., 2006). The version without DAC — often called modified GRF(1–29) — has a much shorter half-life, so the two are not interchangeable in study design.

Ipamorelin: a selective ghrelin-receptor agonist

Ipamorelin is a pentapeptide GHSR-1a agonist. In animal studies it released growth hormone with little effect on ACTH or cortisol at the doses tested, which led its developers to describe it as the first selective GH secretagogue (Raun et al., 1998).

Tesamorelin: a full-length GHRH analogue

Tesamorelin is GHRH(1–44) with a trans-3-hexenoyl group added at the N-terminus for stability. It is the most clinically developed of the three and has been evaluated in randomised controlled trials (Falutz et al., 2007).

Why the two classes are studied together

The GHRH receptor signals mainly through cAMP, while GHSR-1a signals through phospholipase C and intracellular calcium. Because the pathways differ, published studies report synergistic GH release when a GHRH analogue and a ghrelin-receptor agonist are given together — an effect first described with GHRP-class peptides (Bowers et al., 1990). That literature is the basis for research blends that pair the two classes.

Experimental readouts

  • Primary pituitary-cell or somatotroph cultures, with GH released into the medium measured by ELISA.
  • cAMP accumulation assays for GHRH-receptor activity; calcium flux for GHSR-1a activity.
  • Receptor-binding competition assays to confirm target selectivity.
  • Time-course sampling, since pulsatility and receptor desensitisation shape the response.

Selected literature

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006.
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
  3. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007.
  4. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990.

This is not for human consumption. Sold for research only!

This article summarises published laboratory and preclinical research for educational purposes. It is not medical advice and does not describe use in humans or animals.